SCHEMBL994859

SCHEMBL994859

C=CC1CC1(N)C(=O)OC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12891807 1.00
SCHEMBL7638382 1.00
SCHEMBL8025988 1.00
SCHEMBL6117957 1.00
SCHEMBL1952619 1.00
SCHEMBL13757668 1.00
Hydrochloric Acid SCHEMBL29179689 0.98
Hydrochloric Acid SCHEMBL2450453 0.98
Hydrochloric Acid SCHEMBL1255380 0.98
Hydrochloric Acid SCHEMBL4555952 0.98

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2028186-B1 Hepatitis C inhibitor tri-peptides BOEHRINGER INGELHEIM CA LTD (CA) 2013-01-23 EP claimed
EP-2028186-A2 Hepatitis C inhibitor tri-peptides BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2009-02-25 EP claimed
CN-1323316-A Hepatitis C tripeptide inhibitors BOEHRINGER INGELHEIM CA LTD (CA) 2001-11-21 CN claimed
CN-114714713-B Weather-resistant PVC decorative film 江苏万拓新材料科技有限公司 2022-12-30 CN disclosed
CN-114714713-A Weather-resistant PVC decorative film 江苏万拓新材料科技有限公司 2022-07-08 CN disclosed
CN-105861585-B A method of hepatitis C NS3 enzyme inhibitor medicine intermediate is split using Sphingomonas 北京化工大学 2019-08-02 CN disclosed
CN-105861585-A Method for splitting hepatitis c NS3 enzyme inhibitor drug intermediate through sphingomonasaquatilis 北京化工大学 2016-08-17 CN disclosed
US-9353100-B2 Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections IDENIX PHARMACEUTICALS LLC (US) 2016-05-31 US disclosed
EP-2461811-B1 MACROCYCLIC SERINE PROTEASE INHIBITORS USEFUL AGAINST VIRAL INFECTIONS, PARTICULARLY HCV IDENIX PHARMACEUTICALS LLC (US) 2016-04-20 EP disclosed
US-9309279-B2 Macrocyclic hepatitis C serine protease inhibitors ABBVIE INC. (US) 2016-04-12 US disclosed
US-9284307-B2 Macrocyclic serine protease inhibitors IDENIX PHARMACEUTICALS LLC (US) 2016-03-15 US disclosed
US-20090062311-A1 MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS JANSSEN SCIENCES IRELAND UC (IE) 2009-03-05 US disclosed
WO-2009005677-A2 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2009-01-08 WO disclosed
WO-2008086161-A1 MACROCYCLIC HEPATITIS C PROTEASE INHIBITORS PHENOMIX CORPORATION (US) 2008-07-17 WO disclosed
WO-2008057995-A2 HCV PROTEASE INHIBITORS TAIGEN BIOTECHNOLOGY CO., LTD. (TW) 2008-05-15 WO disclosed
US-20080108632-A1 HCV PROTEASE INHIBITORS TAIGEN BIOTECHNOLOGY CO., LTD. (TW) 2008-05-08 US disclosed
WO-2006043145-A1 INHIBITORS OF HEPATITIS C VIRUS PROTEASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME PFIZER INC. (US) 2006-04-27 WO disclosed
US-20040248779-A1 Process for the preparation of macrocyclic compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2004-12-09 US disclosed
US-6268207-B1 RESOLUTION OF ENANTIOMERS FROM A MIXTURE OF (1R,2S)/(1S,2S)-1-AMINO-2-VINYLCYCLOPROPYL CARBOXYLIC ACID METHYL ESTER COMPRISING THE STEP OF TREATING SAID MIXTURE WITH AN ESTERASE TO OBTAIN THE CORRESPONDING (1R,2S) ENANTIOMER BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2001-07-31 US disclosed
US-6268207-B1 RESOLUTION OF ENANTIOMERS FROM A MIXTURE OF (1R,2S)/(1S,2S)-1-AMINO-2-VINYLCYCLOPROPYL CARBOXYLIC ACID METHYL ESTER COMPRISING THE STEP OF TREATING SAID MIXTURE WITH AN ESTERASE TO OBTAIN THE CORRESPONDING (1R,2S) ENANTIOMER BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2001-07-31 US disclosed